SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Down 25.0% in February

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 900 shares, a decrease of 25.0% from the February 13th total of 1,200 shares. Based on an average daily volume of 32,000 shares, the short-interest ratio is presently 0.0 days.

SAB Biotherapeutics Price Performance

Shares of NASDAQ:SABSW traded down $0.00 on Monday, reaching $0.03. 275 shares of the company traded hands, compared to its average volume of 35,229. SAB Biotherapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.18. The company’s 50 day moving average is $0.06 and its 200-day moving average is $0.05.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.